Atlas Trials

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Clinical trial NCT04709276 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04709276
Sponsor
Andrew J. Armstrong, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Cancer
Start date
2021-06-07
Primary completion
2026-02-26
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.